Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huoling Shengji Granules
- Development stage
- Phase 3
- Lead developer
- Shanghai University of Traditional Chinese Medicine
- Administration
- Oral
01
Overview
Huoling Shengji Granules (HLSJ) is a Traditional Chinese Medicine (TCM) formula developed for the treatment of amyotrophic lateral sclerosis (ALS). It is specifically indicated for patients diagnosed with the TCM syndrome of spleen qi deficiency and kidney yang deficiency. The formula consists of six herbal ingredients: Radix Astragali, Epimedium herb, Radix Rehmanniae, Fructus Corni, Atractylodes macrocephala Koidz, and Poria cocos. Preclinical studies in SOD1G93A mouse models have demonstrated that HLSJ can prolong survival, prevent motor neuron loss in the spinal cord, inhibit glial cell activation, and suppress inflammatory responses. The drug is currently being evaluated in Phase II clinical trials in China, comparing its efficacy and safety to riluzole using measures such as the ALSFRS-R and ROADS scales.
- Brand names
- HuolingshengjiHuoling Shengji GranuleHuolingshengji GranulesHLSJ
- Other names
- 藿苓生肌颗粒Huolingshengji Keli granulesHuolingshengji formulaDong Lingsheng Ji Granule
Beyond the preview
Go deeper on Huoling Shengji Granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Huoling Shengji Granules.